Lantheus (NASDAQ:LNTH) Issues Earnings Results

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.45, FiscalAI reports. The company had revenue of $389.91 million during the quarter, compared to analysts’ expectations of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The firm’s revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $1.27 earnings per share.

Lantheus Stock Performance

NASDAQ:LNTH traded down $0.09 during midday trading on Friday, hitting $100.61. The company’s stock had a trading volume of 1,575,979 shares, compared to its average volume of 1,090,931. Lantheus has a fifty-two week low of $50.15 and a fifty-two week high of $111.86. The firm’s 50 day moving average is $100.27 and its 200-day moving average is $92.06. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 2.89. The firm has a market cap of $6.57 billion, a P/E ratio of 24.78 and a beta of 0.01.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LNTH. CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. William Blair set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. Finally, TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, Lantheus has an average rating of “Hold” and an average target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.